Impact of an extensive in situ component on the presence of residual disease in screen detected breast cancer
- PMID: 1744869
- PMCID: PMC1295466
- DOI: 10.1177/014107689108401108
Impact of an extensive in situ component on the presence of residual disease in screen detected breast cancer
Abstract
This study investigates the histopathological characteristics of a consecutive series of 100 screen detected breast cancers in relation to residual disease. Tumour type, size, grade, resection margins and extent of primary or associated in situ disease were all assessed by one pathologist. Thirty-seven women underwent further surgery (wider excision or mastectomy) and the resected specimen was examined for residual in situ or invasive cancer. In total, 36 cancers had an extensive in situ component, of which 69% were predominantly intraduct carcinoma of comedo type. Of the 37 women who underwent further resection, 21 (57%) women had residual cancer. Of those with initial disease at the resection margin, 16/25 (64%) had residual disease. Five of 12 (42%) with disease close to (within 2-3 mm) but not at the margin had residual disease. Of those with an extensive in situ component, 18/25 (72%) had residual disease, whereas only 2/12 (17%) women with none or some in situ disease had residual cancer. In screen detected breast cancer, residual cancer was present in 72% of women with an extensive in situ component at initial surgery. These women comprise a group in which conservation surgery may be inappropriate if completeness of excision is considered a prerequisite for breast conserving surgery.
Similar articles
-
Margins and outcome of screen-detected breast cancer with extensive in situ component.ANZ J Surg. 2006 Jul;76(7):591-5. doi: 10.1111/j.1445-2197.2006.03782.x. ANZ J Surg. 2006. PMID: 16813624
-
Clinicopathologic factors related to surgical margin involvement, reoperation, and residual cancer in primary operable breast cancer - An analysis of 2050 patients.Eur J Surg Oncol. 2018 Nov;44(11):1725-1735. doi: 10.1016/j.ejso.2018.07.056. Epub 2018 Aug 1. Eur J Surg Oncol. 2018. PMID: 30120037
-
A pathologic assessment of adequate margin status in breast-conserving therapy.Ann Surg Oncol. 2006 Mar;13(3):333-9. doi: 10.1245/ASO.2006.03.098. Epub 2006 Feb 10. Ann Surg Oncol. 2006. PMID: 16474911
-
[Margin status in invasive breast cancer].Bull Cancer. 2008 Dec;95(12):1161-70. doi: 10.1684/bdc.2008.0766. Bull Cancer. 2008. PMID: 19091649 Review. French.
-
Close/positive margins after breast-conserving therapy: additional resection or no resection?Breast. 2013 Aug;22 Suppl 2:S115-7. doi: 10.1016/j.breast.2013.07.022. Breast. 2013. PMID: 24074771 Review.
Cited by
-
Imaging-assisted large-format breast pathology: program rationale and development in a nonprofit health system in the United States.Int J Breast Cancer. 2012;2012:171792. doi: 10.1155/2012/171792. Epub 2012 Dec 17. Int J Breast Cancer. 2012. PMID: 23316372 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical